Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation

BACKGROUND: We carried out a phase I trial of the vascular endothelial growth factor inhibitor pazopanib and the histone deacetylase inhibitor vorinostat to determine the safety and efficacy. Because these agents are known to target factors activated by TP53 mutation and facilitate mutant p53 degrad...

詳細記述

保存先:
書誌詳細
出版年:Ann Oncol
主要な著者: Fu, S., Hou, M. M., Naing, A., Janku, F., Hess, K., Zinner, R., Subbiah, V., Hong, D., Wheler, J., Piha-Paul, S., Tsimberidou, A., Karp, D., Araujo, D., Kee, B., Hwu, P., Wolff, R., Kurzrock, R., Meric-Bernstam, F.
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2015
主題:
Original Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6279067/
https://ncbi.nlm.nih.gov/pubmed/25669829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv066
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料